Rosh (1/11 - ...) Flashcards
Treatment for toxo
To stop transmission: spiramycin
To treat current infection in fetus: pyrimethamine, sulfadiazine, folinic acid
FRAX score indicating DEXA
> 9.3%
EPDS downside
Requires population validation
Most common mode of urinary tract injury
Electrosurgery
KRAS
Hereditary colorectal cancer
MSH2
DNA mismatch repair associated with lynch syndrome —> colorectal, endometrial, ovarian
PTEN
Cowden —> hamartomas with risk for breast, endometrial, colorectal, kidney, and thyroid cancer
Mastitis treatment if PCN allergy
Erythromycin
Fetal effect of MS
FGR, birth defects
Cervical cancer type by HPV type
Squamous 16
Adenocarcinoma 18
Chemo for cervical cancer
Cisplatin
To counteract toxic effects of MTX… it
Leucovorin
How do OCPs treat hirsutism?
Increase liver production of sex hormone binding globulin which then bind androgens
Second line agents for hirsutism
Spironolactone, flutamide, finasteride, cyproterone acetate
Mechanism of finasteride
5-alpha reductase inhibitor to stop testosterone conversion to active DHT
Spironolactone mechanism
Antagonist to aldosterone and androgen receptor
Flutamide mechanism
Anti androgen
Chemo for granulosa cell tumor
Bleomycin, etoposide, cisplatin (BEP)
Effects of ace inhibitors on fetus
Renal and limb abnormalities -> oligohydramnios and possible pulmonary hypo plasma
Embryologic origins of Gartner duct cysts
Mesonephric ducts
Embryologic origin of ovary
Genital ridge
Embryologic origin of uterus, fallopian tubes, upper vagina
Paramesonephric ducts
Embryologic origin of labia minora
Urogenital folds
Embryologic origin of the urogenital system
Intermediate mesoderm
Relationship of obesity and breast cancer risk
Premenopausal, protective
Postmenopausal, higher risk
Treatment for magnesium toxicity
15-30 mL of calcium gluconate 10% solution IV
Cancer risk with Paget’s disease
20% have invasive adenocarcinoma
Pre-operative evaluation in Paget’s disease
Mammogram, colonoscopy, pap – risk of additional sites of involvement
Treatment for hyperprolactinemia
Twice weekly cabergoline
Posterior pituitary hormones
ADH (vasopressin) and oxytocin
Neurohypophysis, cell bodies in hypothalamus and directly released through posterior pituitary
Hypothalamus hormones
Releasing hormones: GHRH, TRH, GnRH, etc
Anterior pituitary hormones
Prolactin, TSH, GH, ACTH, LH, FSH
Dopamine
Inhibits prolactin production
Cabergoline
Dopamine agonist
Endometriosis increases risk of what cancer?
Endometrioid adenocarcinoma or clear cell
Contraindications to live flu vaccine
Immunocompromised, pregnant, age >50 y/o
Most common site of endometriosis
Ovary, uterosacral ligaments
Bowel, after definitive hyst, BSO
Amsel criteria
To diagnose BV, 3/4 present:
- Whiff test
- Clue cells
- pH >4.5
- Thin white discharge
Fastest treatment of hirsuit hair growth
Eflornithine cream (6-8 wks), inhibits ornithine decarboxylase
Best SSRI’s while breastfeeding
Sertraline, paroxetine
Antidepressant contraindicated with history of seizure
Bupropion
Vaccines safe in pregnancy
Hep B, flu, Tdap, meningococcal, rabies
Embryologic origin of the Bartholin’s gland
Urogenital sinus
When to biopsy a Bartholin’s cyst
> 40 y/o
Characteristics of type 2 endometrial cancer
Papillary serous, clear cell, carcinosarcoma – no association with estrogen, occur at older age (>60y/o), more agressive, more often p53 mutation
Ideal day of embryo transfer after fertilization
Day 5 - blastocyst
Hormone causing lighter, finer hair growth
Estradiol
Most common immune cell in decidua in early pregnancy
Natural killer cell
Lynch syndrome screening
EMBx and pelvic exam annually starting at 30 y/o
Serum marker associated with placenta accreta
AFP
When to do EMBx
Age >45 y/o or risk factors like obesity
Branches of SMA
Right, middle, and ileocolic arteries
Branches of IMA
Left colic and sigmoid arteries
Omental blood supply
R/L gastroepiploic, gastroduodenal, common hepatic, splenic
Branches of external iliac
Inferior epigastric, deep circumflex iliac, becomes femoral artery
Posterior division of internal iliac
Superior gluteal, iliolumbar, lateral sacral
Anterior division of internal iliac
Umbilical (to superior vesicle), uterine (to vaginal), middle rectal, obturator, inferior gluteal, internal pudendal
Ovarian arteries
From aorta, below renal arteries
Supply ovaries, fallopian tubes, broad ligament, ureters
Ovarian veins
Left to renal vein, right to IVC
Quad weakness, lost knee extension, thigh numbness (medial, upper)
Femoral nerve (retractor or extreme hip flexion / rotation)
Anterior and posterior thigh pain / paresthesias
Lateral femoral cutaneous (retractor compression)
Numb vulva
Genitofemoral (during LND)
Lost adduction of thigh, upper medial thigh numbness
Obturator nerve (during LND or TOT)
Sharp pain from incision downward
Ilioinguinal / iliohypogastric (entrapped during fascial closure)
Sciatica
Sciatic nerve (long surgery, asst leans on thigh)
Foot drop
Common peroneal (knee in stirrups)
Butt pain
Pudendal (during sacrospinous ligament fixation)
Unable to use arm
Brachial plexus (stretch)
Claw hand
Ulnar (elbow compression)
Nerve running along psoas
Genitofemoral
Referral to onc for premenopausal adnexal mass
CA-125 > 200 and concerning TVUS
Most common ovarian cancer mets
Endometrial, breast, GI tract
VTE, hypercalcemia, hyperpyrexia, unilateral adnexal mass, early mets
Clear cell (epithelial) ovarian cancer
Schiller Duval bodies
Endodermal sinus tumor (yolk sac)
Virilization and amenorrhea with adnexal mass
Sertoli-Leydig tumor
Dysgerminoma markers
Beta hcg, LDH
Endodermal sinus markers
AFP
Choriocarcinoma markers
Beta hcg
Immature teratoma markers
AFP, LDH, CA-125
Embryonal carcinoma markers
Beta hcg, AFP
Granulosa cell marker
Inhibin B
Ovarian cancer stage with chemo required
IC – capsule rupture and/or positive washings
Stage 2 ovarian cancer
Pelvic organs
Stage 3 ovarian cancer
Peritoneal surfaces with mets
Stage 4 ovarian cancer
Pleural effusion with positive cytology, hepatic / splenic mets
Endometrial hyperplasia classifications
Benign (no atypia) or intrapithelial neoplasia (atypia, precancer)
Stage 1 endometrial cancer
A <50% myometrium
B >50% myometrium
Stage 2 endometrial cancer
Cervical stroma
Stage 3 endometrial cancer
A serosa or adnexa
B vaginal or parametrial
C1 pelvic LN
C2 paraaortic LN
Stage 4 endometrial cancer
A bladder or bowel
B distant met
Most common cause of death in cervical cancer
Uremia
HPV oncoproteins
E6 inhibits p53
E7 inhibits Rb
Cancer associated with DES
Vaginal adenocarcinoma (most other vaginal cancer is squamous)
Lymphtic drainage of vagina
Upper 2/3 to pelvic nodes
Lower 1/3 to inguinal
Cervical cancer mets
Lung, liver, bony
Theca lutein cysts associated with
Complete mole (not partial) – due to excessive beta hcg
Percent of moles that become invasive
10-15%
Monitoring following mole
Weekly beta hcg until neg x 3 weeks, then q4wks x 6-12 mos
Dx of GTN
Plateau of beta hcg x 4 measurements OR rise >10% in 3 wks, or hcg still detectable 6 mos later
GTD treatment
MTX or actinomycin D for low risk
EMA-CO for high risk
Mechanism of doxorubicin, bleomycin, antinomycin D
Free oxygen radicals
Mechanism of etoposide, vincristine
Inhibits topoisomerase
Mechanism of taxanes
Inhibits microtubule polymerization
Mechanism of platinums
Cross links DNA subunits
Mechanism of bavacizumab
VEG-F inhibitor
Mechanism of cyclophosphamide
Cross-link
Alopecia
Taxanes, antinomycin
Cardiotoxicity
Doxorubicin
Hemorrhagic cystitis
Cyclophosphamide
Interstitial pneumonitis
Doxorubicin
Nephrotoxicity
Cisplatin
Pulmonary fibrosis
Bleomycin
Secondary malignancy
Etoposide
Peripheral neuropathy
Taxol
Timing for risk-reducing BSO
BRCA1: 35-40 y/o
BRCA2: 40-45 y/o